- 1 **Title**: Machine Learning to Predict Mortality and Critical Events in COVID-19 Positive
- 2 New York City Patients
- 3
- 4 Short Title: Predicting COVID-19 Outcomes With Machine Learning
- 5

# 6 **One-Sentence Summary**:

- 7 We identify clinical features that robustly predict mortality and critical events in a large
- 8 cohort of COVID-19 positive patients in New York City.
- 9

# 10 Authors:

- 11 Akhil Vaid<sup>1</sup>, Sulaiman Somani<sup>1+</sup>, Adam J Russak<sup>1,2+</sup>, Jessica K De Freitas<sup>1,3</sup>, Fayzan F
- 12 Chaudhry<sup>1,3</sup>, Ishan Paranjpe<sup>1</sup>, Kipp W Johnson<sup>3</sup>, Samuel J Lee<sup>1</sup>, Riccardo Miotto<sup>1,3</sup>,
- 13 Shan Zhao<sup>1,4</sup>, Noam D Beckmann<sup>3</sup>, Nidhi Naik<sup>1</sup>, Kodi Arfer<sup>5</sup>, Arash Kia<sup>6,7</sup>, Prem
- 14 Timsina<sup>6,7</sup>, Anuradha Lala<sup>6,8</sup>, Manish Paranjpe<sup>9</sup>, Patricia Glowe<sup>1</sup>, Eddye Golden<sup>1</sup>,
- 15 Matteo Danieletto<sup>1</sup>, Manbir Singh<sup>1</sup>, Dara Meyer<sup>3</sup>, Paul F O'Reilly<sup>3,10,11</sup>, Laura H
- 16 Huckins<sup>3,10,11</sup>, Patricia Kovatch<sup>12</sup>, Joseph Finkelstein<sup>6</sup>, Robert M Freeman<sup>6,7</sup>, Edgar
- 17 Argulian<sup>13,14</sup>, Andrew Kasarskis<sup>3,6,15,16</sup>, Bethany Percha<sup>2</sup>, Judith A Aberg<sup>2,17</sup>, Emilia
- 18 Bagiella<sup>7,8,</sup>, Carol R Horowitz<sup>2,6</sup>, Barbara Murphy<sup>2</sup>, Eric J Nestler<sup>18,19</sup>, Eric E Schadt<sup>3,15</sup>,
- 19 Judy H Cho<sup>20</sup>, Carlos Cordon-Cardo<sup>21</sup>, Valentin Fuster<sup>8,13,14</sup>, Dennis S Charney<sup>22</sup>, David
- L Reich<sup>4</sup>, Erwin P Bottinger<sup>1,2</sup>, Matthew A Levin<sup>4</sup>, Jagat Narula<sup>13,14</sup>, Zahi A Fayad<sup>23,24</sup>,
- 21 Allan C Just<sup>5\*</sup>, Alexander W Charney<sup>3,10,11\*</sup>, Girish N Nadkarni<sup>1,2,18\*</sup>, Benjamin S
- 22 Glicksberg<sup>1,3\*</sup> on behalf of the Mount Sinai Covid Informatics Center (MSCIC).
- 23

26

24 + Equal contribution

- 25 \*Co-correspondence
- 27 Affiliations:
- The Hasso Plattner Institute for Digital Health at Mount Sinai, Icahn School of
   Medicine at Mount Sinai
- 30 2. Department of Medicine, Icahn School of Medicine at Mount Sinai
- 3. Department of Genetics and Genomic Sciences, Icahn School of Medicine at
   Mount Sinai
- Department of Anesthesiology, Perioperative and Pain Medicine, Icahn School of
   Medicine at Mount Sinai
- 5. Department of Environmental Medicine and Public Health, Icahn School of
   Medicine at Mount Sinai
- Bepartment of Population Health Science and Policy, Icahn School of Medicine
   at Mount Sinai
- 39 7. Institute for Healthcare Delivery Science, Icahn School of Medicine at Mount40 Sinai

41 42	<ol> <li>The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai</li> </ol>
42 13	9 Harvard Medical School
43 44	10 The Pamela Sklar Division of Psychiatric Genomics, Icahn School of Medicine at
45	Mount Sinai
46	11. The Department of Psychiatry, Icahn School of Medicine at Mount Sinai
47	12. Mount Sinai Data Warehouse, Icahn School of Medicine at Mount Sinai
48	13. Mount Sinai Heart, Icahn School of Medicine at Mount Sinai
49	14. Department of Cardiology, Icahn School of Medicine at Mount Sinai
50	15. Icahn Institute for Data Science and Genomic Technology, Icahn School of
51	Medicine at Mount Sinai
52	16. Mount Sinai Data Office Icahn School of Medicine at Mount Sinai
53	17. Division of Infectious Diseases, Icahn School of Medicine at Mount Sinai
54	18. Nash Family Department of Neuroscience, Icahn School of Medicine at Mount
55	Sinai
56	19. Friedman Brain Institute, Icahn School of Medicine at Mount Sinai
57	20. The Charles Bronfman Institute for Personalized Medicine, Icahn School of
58	Medicine at Mount Sinai
59	21. Department of Pathology, Icahn School of Medicine at Mount Sinai
60	22. Office of the Dean, Icahn School of Medicine at Mount Sinai
61	23. BioMedical Engineering and Imaging Institute, Icahn School of Medicine at Mount
62	Sinai
63	24. Department of Radiology, Icahn School of Medicine at Mount Sinai
64	
65	Ξ' 0
66	Figures: 3
67	
68	Word Count: 3120
69	
70	Correspondence:
71 72	Allan Just PhD
73	allan just@mssm.edu
74	
75	Alexander Charney, MD, PhD
76	alexander.charney@icahn.mssm.edu
77	
78	Girish Nadkarni, MD
79	girish.nadkarni@mountsinai.org
80	

- 81 Benjamin Glicksberg, PhD
- 82 benjamin.glicksberg@mssm.edu

83

#### 85 Abstract

Coronavirus 2019 (COVID-19), caused by the SARS-CoV-2 virus, has become the 86 deadliest pandemic in modern history, reaching nearly every country worldwide and 87 overwhelming healthcare institutions. As of April 20, there have been more than 2.4 88 89 million confirmed cases with over 160,000 deaths. Extreme case surges coupled with challenges in forecasting the clinical course of affected patients have necessitated 90 thoughtful resource allocation and early identification of high-risk patients. However, 91 effective methods for achieving this are lacking. In this paper, we use electronic health 92 records from over 3,055 New York City confirmed COVID-19 positive patients across 93 94 five hospitals in the Mount Sinai Health System and present a decision tree-based 95 machine learning model for predicting in-hospital mortality and critical events. This model is first trained on patients from a single hospital and then externally validated on 96 patients from four other hospitals. We achieve strong performance, notably predicting 97 98 mortality at 1 week with an AUC-ROC of 0.84. Finally, we establish model interpretability by calculating SHAP scores to identify decisive features, including age, 99 inflammatory markers (procalcitonin and LDH), and coagulation parameters (PT, PTT, 100 D-Dimer). To our knowledge, this is one of the first models with external validation to 101 102 both predict outcomes in COVID-19 patients with strong validation performance and identify key contributors in outcome prediction that may assist clinicians in making 103 effective patient management decisions. 104 105

#### 107 Introduction

108 Despite substantial, organized efforts to prevent disease spread, over 2.4 million people

- 109 have tested positive for SARS-CoV-2 worldwide, and there have been more than
- 110 169,000 deaths to date(1-3). As a result of this pandemic, hospitals are being filled
- 111 beyond capacity and face extreme challenges with regards to personnel staffing,
- 112 personal protective equipment availability, and ICU bed allocation. Additionally, patients
- 113 with COVID-19 demonstrate varying symptomatology, making successful and safe
- 114 patient triaging difficult. While some infected patients are asymptomatic, others suffer
- 115 from severe acute respiratory distress syndrome, multiorgan failure, and death(4).
- 116 Identification of key patient characteristics that govern the course of disease across
- 117 large patient cohorts is lacking but important, particularly given the potential it has to aid
- 118 physicians and hospitals in predicting disease trajectory, to allocate essential resources
- effectively, and to improve patient outcomes. With these needs in mind, we report the
- development of a decision tree-based machine learning model trained on electronic
   health records from patients with confirmed COVID-19 status at a single center in the
- 122 Mount Sinai Health System in New York City to predict critical events and mortality;
- validate this algorithm at four other hospital centers; and perform a saliency analysis
- 124 using SHAP (SHapley Additive exPlanation) values to identify the most important
- 125 features used by this model for outcome prediction.
- 126

# 127 **Results**

- 128 Clinical Data Source and Study Population
- 129 We retrieved electronic health records for 3,055 COVID-19-positive inpatient
- 130 admissions at five hospitals between March 9, 2020 and April 11, 2020 within the Mount
- 131 Sinai Health System (MSHS). These data included patient demographics, past medical
- history, and admission vitals and labs (Table 1, Supplementary Table 2). Relevant
- 133 patient events (intubation, discharge to hospice care, or death) were recorded and
- 134 subsets were constructed at 3, 5, 7, and 10 day intervals after admission (Figure 1). Of
- these patients, 17.0% to 31.6% had a critical event (intubation, discharge to hospice
- care, or death) and 6.0% to 21.5% died over the observed time frames (Supplementary
- Table 1). In contrast, the control group consisted of patients with all other discharge
- 138 dispositions and those that were still hospitalized.
- 139
- 140 Classifier training and performance
- 141 Given the large number of patients in the analysis and presence of missing variables in
- 142 the data, we used XGBoost(5), a boosted decision-tree based machine learning (ML)
- 143 model, to predict either a critical event or death of a patient within the aforementioned
- time frames. Patients from the Mount Sinai Hospital (MSH) were split into a training and
- validation set for the model. To increase model generalizability and help minimize bias,
- 146 the model's performance was assessed on a test set composed entirely of patients from

147 the other hospitals (OH) in the MSHS. While multiple time limits for event occurrence

148 were assessed, the results and discussion in this letter focus predominantly one week

149 after admission. As a control, both simple and generalized additive logistic regression

150 models were trained to assess performance, given their ubiquity as the preferred model

- 151 in current COVID research pieces.
- 152

153 After training, the classifier robustly predicted the presence of a critical event at three, five, seven, and 10 days (Figure 2 and Supplementary Table 4) as measured by area 154 under the receiver operating characteristic curve (AUC-ROC = 0.74 for OH, 0.83 for 155 156 MSH at 1 week) and area under the precision-recall curve (AUPRC = 0.58 for OH, 0.49 157 for MSH at 1 week). We were able to achieve similar performance at predicting critical events at longer intervals, namely 15 and 20 days (Supplementary Table 5). As a 158 159 baseline comparison, the logistic regression models (Supplementary Table 6) performed more poorly in prediction by AUC-ROC (0.52 - 0.74) and AUC-PRC (0.19 -160 (0.37) for critical events at three days relative to the XGBoost model (AUC-ROC = 0.77, 161 162 AUC-PRC = 0.43). With respect to mortality, the model achieved high specificity (0.79 -0.92 for OH) and AUC-ROC (0.79 - 0.92 for OH) with similar AUPRC (0.38 - 0.65 OH) 163 164 as with critical events. As the event time window increased, the performance of the classifier by the AUPRC value improved, which likely stems from the infrequency of 165 deaths at earlier time points that created a class imbalance for mortality. Comparatively, 166

167 all logistic regression models underperformed significantly in prediction by AUC-ROC

168 (0.61-0.70) and AUC-PRC (0.06 - 0.18) for mortality.

169

# 170 Identifying important features in the model

171 To identify the most salient features driving model prediction, SHAP (SHapley Additive exPlanations) values(6) were calculated for the highest-performing model in the cross-172 173 validation set during hyperparameter tuning (Figure 3). Among the top features, both high and low levels of lactate dehydrogenase (LDH), procalcitonin, and D-dimer were 174 strong drivers for predicting a critical event at 1 week, while elevated prothrombin time 175 (PT) and partial thromboplastin time (PTT) favored the classifier to predict a critical 176 177 event. For mortality, both high and low values for age, procalcitonin, and red blood cell distribution width (RDW) were the strongest effectors in guiding mortality prediction by 178 179 the model within 1 week of admission. Other important variables for increasing the 180 prediction for death included an elevated troponin, LDH, lymphopenia (i.e. low 181 lymphocyte percentage), white blood cell count (WBC), aspartate aminotransferase 182 (AST), and D-dimer. Finally, using SHAP interaction scores, we discovered that 183 covariate interactions between features, relative to each feature's independent importance, contributed less to the model's prediction (Supplementary Figures 1-4). 184 185

186 Discussion

187 We highlight several important findings that have implications in clinical medicine. First. we offer robust prediction algorithms pertaining to the most clinically severe outcomes 188 based solely on admission metrics. This insight provides the likely hospital course for 189 patients up to 10 days into the future. High sensitivity in predicting mortality within three, 190 191 five, and seven days of admission (0.86 - 1.0) suggests that this model can potentially be used by clinicians in gauging the acute clinical course of an admitted patient. The 192 model's high specificity, particularly for mortality at days three (specificity = 0.92) and 193 five (specificity = 0.86), suggest its role for augmenting clinicians' decision-making when 194 identifying patients at immediate risk of impending clinical decompensation and 195

- 196 potentially guide allocation of more intensive care upon admission.
- 197

Additionally, our framework permits a clinically relevant understanding of the model's
 most salient features defining its decision boundaries. Age was the most important
 feature for mortality prediction in COVID-19+ patients, with a notable exponential rise of

- feature contribution as age increased (Figure 3)(7, 8). Elevations in serum LDH,
- although nonspecific markers of inflammation, are implicated in pulmonary endothelial
- cell injury and in COVID-19+ patients (9–11). Equivalently, procalcitonin has been
- implicated as a biomarker of underlying infection and sepsis risk(12, 13). Elevated
- RDW, which may be an index for enhanced patient frailty and risk of adverse
- 206 outcomes(14), was also a strong driver of mortality. Other salient features like
- leukocytosis (15), a natural response to inflammation, in combination with virally-driven
- lymphopenia (16, 17), have also been associated with COVID-19 burden. Additionally,
- elevated troponins(18, 19), renal dysfunction from elevated creatinine(20), anemia, vital
   instability (low oxygen saturation, tachycardia, hypotension), elevated ferritin(10, 19),
- instability (low oxygen saturation, tachycardia, hypotension), elevated ferritin(10, 19),
   high lactate, and acidosis were also contributors to driving model prediction towards
- mortality. With growing evidence of COVID-19-induced hypercoagulable states in these
- patients (10, 21, 22), it is promising that our model recognized the feature importance of
- coagulability markers, such as PT, PTT, and D-dimer (Figure 3). Thus, this
- corroboration of the features learned by XGBoost and highlighted by the SHAP analysis
- 216 with those findings from pathophysiological principles and more recent correlative
- studies exploring COVID-19 patients (2, 3, 18, 23–25) gives additional credibility to these
  findings.
- 219

Just as interesting as the features present in the SHAP value analysis were those that were not. For example, because race is both poorly represented ("Unknown") and categorized inadequately in electronic health records, the model did not find race to be important for outcome prediction and instead opted to favor more objective data (vitals, labs). Contrary to our expectation, age was not identified as a significant feature for critical event prediction in these primary analyses. However, SHAP value analyses for critical event prediction at longer time frames (10, 15, and 20 days) revealed an

increasing importance on age for outcome prediction (Supplementary Figure 5). This

- trend suggests the model's decision to capture acute events by relying on more
- 229 objective measures not confounded by other factors that are cached into age, which
- may better represent illness severity. However, over time, age may become a better
- 231 marker for critical event prediction, by offering a more stable container of clinical
- information, given its invariance to change relative to other features. As such, the
- 233 classifier becomes optimized for predicting severe events earlier in the course of illness.
- 234

The results of our models should be considered in light of several limitations. First, we 235 236 base our predictions solely on a patient's admission labs (i.e. within 36 hours); while this 237 restriction encourages the use of this model in patient triage, events during a patient's 238 hospital stay after admission may drive their clinical course away from the prior 239 probability. Furthermore, not all patient labs are drawn at admission, which introduces 240 an element of missingness in our dataset. For example, unlike the general patient 241 population, patients on anticoagulation therapy, who likely have comorbidities 242 increasing their baseline risk, will have coagulation labs (PT, PTT) taken on admission. However, the shift away from predicting death by the model in the absence of PT/PTT 243 244 (Figure 3) suggests that missingness in coagulation labs is a proxy for this lower baseline risk secondary to not having comorbid conditions that require anticoagulation 245 therapy. Additionally, patients admitted to the hospital later in the crisis were both 246 beneficiaries of improved patient care protocols from experiential learning, but also 247 victims of resource constraints from overburdened hospitals. These effects, while 248 249 possibly negated by our large sample size, may also induce temporal variation between patient outcomes. Furthermore, inherent limitations exist when using EHRs, especially 250 those integrated from multiple hospitals. In order to facilitate timely dissemination of our 251 results, we chose not to manually chart review patient notes that may have otherwise 252 253 provided additional potential features, such as symptoms and clinical course, to incorporate in our model. Because all five hospitals operate in a single health system, 254 255 system-wide protocols in lab order sets and management protocols were an additional 256 source of bias that may lower external validity. Other interhospital effects such as 257 shuttling COVID-19 cases to certain hospitals for balancing systemic patient burden 258 may also imbalance case severity across hospitals and care management between 259 hospitals; certainly, this was the case for MSW, where mortality at 3-days was far lower 260 (1.7%) than other hospital sites. This was ultimately a major reason to restrict model 261 training to a single center and perform testing out of sample in another hospital center. 262 Finally, though XGBoost is superior to other models at handling missing data, a notable 263 drawback is its bias towards continuous features instead of categorical ones, given increased information represented in the form (28). However, collinearities between 264 some categorical features in this dataset may be present with other continuous features, 265 266 as exhibited by covariance strength between hypertension and systolic BP and

creatinine in Supplemental Figure 4, which can then serve as vehicles for capturingthese categorical pieces of information.

269

270 In conclusion, the COVID-19 pandemic unequivocally represents an unprecedented 271 public health crisis. Healthcare institutions are facing extreme difficulties in managing 272 resources and personnel. Physicians are treating record numbers of patients and 273 continuously expose themselves to a highly contagious and virulent disease with varying symptomatology. Only few therapeutic options have demonstrated improvement 274 to patient outcomes. As COVID-19 moves outside of the current epicenter in New York 275 276 City, healthcare institutions will see a larger influx of affected patients and can benefit 277 from immediate insights regarding assessment of disease severity (29, 30). These 278 models successfully predict critical illness and mortality up to 10 days in advance in a 279 diverse patient population from admission information alone and provide important 280 markers for acute care prognosis that can be used by healthcare institutions to improve 281 care decisions at both the physician and hospital level for management of COVID-19 282 positive patients. 283 284 **Materials and Methods** 285 This study has been approved by the Institutional Review Board at the Icahn School of 286 Medicine at Mount Sinai (IRB- 20-03271). 287 288 289 Clinical Data Source and Study Population In this study, patient data came from five hospitals within the Mount Sinai Hospital 290 System (MSHS): the Mount Sinai Hospital (MSH) located in East Harlem, Manhattan; 291 Mount Sinai Morningside (MSM) located in Morningside Heights, Manhattan; Mount 292 293 Sinai West (MSW) located in Midtown and the West Side, Manhattan; Mount Sinai

- 295 in Astoria, Queens. The dataset was obtained from different sources and aggregated by
- the Mount Sinai COVID Informatics Center (MSCIC).
- 297

294

We included patients who were over 18 years old that had a laboratory-confirmed COVID-19 infection, and were admitted between March 9 and April 11, 2020 to any of

Brooklyn (MSB) located in Midwood, Brooklyn; and Mount Sinai Queens (MSQ) located

- the hospitals previously mentioned. A confirmed case of COVID-19 was defined by a
- 301 positive reverse transcriptase polymerase chain reaction (RT-PCR) assay of a
- 302 nasopharyngeal swab. We excluded patients who had a positive COVID-19 RT-PCR
- 303 result more than two days after admission. Additional exclusion criteria are presented in
- Figure 1. Full patient characteristics by site are provided in Supplementary Table 1.
- 305

306 Study Data

Demographics included age, sex, as well as reported race, and ethnicity. Race was 307 collapsed into seven categories based off of the most recent US census race 308 categories: American Indian or Alaskan Native, Asian, Black or African-American, 309 310 Other, Native Hawaiian or Other Pacific Islander, Unknown, and White. Ethnicity was 311 collapsed into three categories: Hispanic/Latino, Non-Hispanic/Latino, and Unknown. 312 We obtained demographics, diagnosis codes (International Classification of Diseases-313 9/10-Clinical Modification (ICD-9/10-CM) codes and procedures), as well as vital signs and laboratory measurements during hospitalization. A pre-existing condition was 314 defined as the presence of ICD-9/10-CM codes associated with specific diseases. We 315 316 chose to include as covariates conditions that have been previously reported to have 317 increased incidence in hospitalized COVID-19 patients, specifically: atrial fibrillation, 318 asthma, cancer, coronary artery disease, chronic kidney disease, chronic obstructive 319 pulmonary disease, diabetes mellitus, heart failure, hypertension, and stroke(15, 23-25,

320 *31)*.

321

322 We included laboratory measurements and vital signs near the time of admission for 323 prediction. Specifically, because records for laboratory values and vitals may appear 324 with some lag, only the first available value within 36 hours of admission was included. otherwise the value was assigned as missing. Height was absent in a large percentage 325 of the patients (18.2%). Because height is generally invariant in the adult population, 326 327 and given the resource constraint of the pandemic, it was common for triage nurses to use the height from a previous and recent admission. In an effort to be as cohesive in 328 329 our data gathering methods as possible, these earlier records were not retrieved for this dataset. However, weight was used as the next approximate proxy for body habitus, 330 331 with additional information being presented through sex and age for body habitus as 332 well.

333

All lab orders from the five hospitals were queried for patients included in this study 334 within the timeframe of interest. Due to discrepancies in how labs were named in 335 336 different hospitals, a comprehensive review of all lab field names was conducted by a 337 multidisciplinary team of clinical and statistical experts to ensure that there was a direct 338 mapping between all sites. Additionally, many labs represented a single component 339 (e.g. sodium), but were acquired from either an arterial blood gas (ABG), venous blood 340 gas (VBG), and basic metabolic panel (BMP). Based on the utility of these lab values in 341 clinical practice and the similarity between their statistical distributions, labs derived 342 from a VBG or BMP were collapsed into a single category (i.e. 'SODIUM') and those 343 derived from an ABG were moved to a separate category (i.e. 'SODIUM\_A'). Finally, the earliest lab, by time of result, in the set of all lab order names that were combined into a 344 345 single lab category was chosen as the representative lab value for that category. 346 Finally, lab data below the 0.5th and above the 99.5th percentiles were removed to

347 avoid inclusion of any obvious outliers that could represent incorrect documentation and 348 measurement error.

349

- 350 Definition of Outcomes
- 351 The two primary outcomes were 1) death versus survival or discharge, and 2) critical
- 352 illness versus survival or discharge, through time horizons of 3, 5, 7, and 10 days.
- 353 Critical illness is defined as discharge to hospice, intubation  $\leq$  48 hours prior to ICU
- 354 admission, or death. To address potential concerns of censoring by limiting exploration
- of only these time frames, particularly in the case of model enrichment for acute critical 355
- events, we also predicted critical events at days 15 and 20. 356
- 357

#### 358 Statistical Analysis

- 359 Our primary model was fit with the Extreme Gradient Boosting (XGBoost)
- 360 implementation of boosted decision trees on continuous and one-hot encoded
- 361 categorical features. The XGBoost algorithm provides state-of-the-art prediction results
- 362 through an iterative process of averaging in decision trees (we used 100) fit to the
- residual error of the prior ensemble. While each tree is too simple to accurately capture 363
- 364 complex phenomena, the combination of many trees in the XGBoost model 365 accommodates non-linearity and interactions between predictors. Missing data values
- are routed through split points based on the direction to minimize loss. XGBoost models 366
- 367 were trained and evaluated using 10-fold stratified cross validation. For each fold,
- hyperparameter tuning was performed by randomized grid searching directed towards 368
- 369 maximizing the sensitivity metric over 2,000 discrete grid options. Cross-validation was
- 370 performed inside each grid option. We present the model hyperparameters for all 371 experiments in Supplementary Table 3. The performance of the models were measured
- 372
- using the area under the receiver operator characteristic curve (AUC-ROC), area under 373 the precision-recall curve (AUC-PRC), F1-score, sensitivity, and specificity. To interpret
- the significance of input features on the model's prediction, SHAP values across all 374
- 375 features on the best-performing model, by AUC-ROC, in the cross-validation set were
- 376 calculated. Finally, we tested these models built on patient data from MSH on patients
- 377 from four other hospitals (Figure 1).
- 378

379 As a baseline, we also fit a logistic regression model and a generalized additive logistic 380 model to compare our XGBoost model. We decided to use a generalized additive model 381 because of its ability to extend generalized linear models by allowing for non-linear 382 functions of features. Four main models were generated: 1) Logistic regression using 383 only Age 2) Generalized Additive Model using only Age 3) Logistic Regression with all 384 available features 4) Generalized Additive Model using all available features. Since

- these models do not have a built in method of dealing with missing data, we dropped
- 386 features with over 70% missingness and samples that lacked values for the remaining
- 387 feature space. The models were trained and evaluated using 10-fold stratified cross
- validation on patient data from MSH and subsequently evaluated on patient data from
- the other hospitals. The same metrics were recorded for these models; however, this
- model was only trained at outcome prediction on Day 3, which was the time frame at
- 391 which model AUC-ROC was highest for the XGBoost classifier. Performance results for
- this classifier are represented in Supplementary Table 5.

#### 393 References

1. G. Onder, G. Rezza, S. Brusaferro, Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy*JAMA* (2020),

396 doi:10.1001/jama.2020.4683.

2. W.-J. Guan, Z.-Y. Ni, Y. Hu, W.-H. Liang, C.-Q. Ou, J.-X. He, L. Liu, H. Shan, C.-L.
Lei, D. S. C. Hui, B. Du, L.-J. Li, G. Zeng, K.-Y. Yuen, R.-C. Chen, C.-L. Tang, T. Wang,
P.-Y. Chen, J. Xiang, S.-Y. Li, J.-L. Wang, Z.-J. Liang, Y.-X. Peng, L. Wei, Y. Liu, Y.-H.
Hu, P. Peng, J.-M. Wang, J.-Y. Liu, Z. Chen, G. Li, Z.-J. Zheng, S.-Q. Qiu, J. Luo, C.-J.
Ye, S.-Y. Zhu, N.-S. Zhong, China Medical Treatment Expert Group for Covid-19,
Clinical Characteristics of Coronavirus Disease 2019 in China, *N. Engl. J. Med.* (2020),
doi:10.1056/NEJMoa2002032.

- 404 3. E. Livingston, K. Bucher, Coronavirus Disease 2019 (COVID-19) in Italy*JAMA* 323,
  405 1335 (2020).
- 406 4. K. Mizumoto, K. Kagaya, A. Zarebski, G. Chowell, Estimating the asymptomatic
  407 proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond
  408 Princess cruise ship, Yokohama, Japan, 2020, *Eurosurveillance* 25, 2000180 (2020).
- 409 5. T. Chen, C. Guestrin, XGBoost: A Scalable Tree Boosting System (2016),
   410 doi:10.1145/2939672.2939785.
- 6. S. M. Lundberg, S.-I. Lee, in *Advances in Neural Information Processing Systems*,
  (2017), pp. 4765–4774.
- 413 7. K. Wang, P.-Y. Zuo, Y. Liu, M. Zhang, X. Zhao, S. Xie, H. Zhang, X. Chen, C. Liu,
- 414 Clinical and Laboratory Predictors of In-Hospital Mortality in 305 Patients with COVID-
- 415 19: A Cohort Study in Wuhan, China, (2020), doi:10.2139/ssrn.3546115.
- 8. Q. Ruan, K. Yang, W. Wang, L. Jiang, J. Song, Clinical predictors of mortality due to
  COVID-19 based on an analysis of data of 150 patients from Wuhan, China, *Intensive Care Med.*, 1–3 (2020).
- 419 9. M. Drent, N. A. Cobben, R. F. Henderson, E. F. Wouters, M. van Dieijen-Visser,
- Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation, *Eur. Respir. J.* **9**, 1736–1742 (1996).
- 422 10. E. Terpos, I. Ntanasis-Stathopoulos, I. Elalamy, E. Kastritis, T. N. Sergentanis, M.
  423 Politou, T. Psaltopoulou, G. Gerotziafas, M. A. Dimopoulos, Hematological findings and
  424 complications of COVID-19, *Am. J. Hematol.* (2020), doi:10.1002/ajh.25829.
- 11. B. M. Henry, M. H. S. de Oliveira, S. Benoit, M. Plebani, G. Lippi, Hematologic,
  biochemical and immune biomarker abnormalities associated with severe illness and
  mortality in coronavirus disease 2019 (COVID-19): a meta-analysis, *Clin. Chem. Lab.*Mod (2020) doi:10.1515/colm.2020.0260
- 428 *Med.* (2020), doi:10.1515/cclm-2020-0369.

429 12. A. L. Vijayan, Vanimaya, S. Ravindran, R. Saikant, S. Lakshmi, R. Kartik, M. G,

- 430 Procalcitonin: a promising diagnostic marker for sepsis and antibiotic therapy, *J.* 431 *Intensive Care Med.* 5, 51 (2017).
- 432 13. J. T. Poston, B. K. Patel, A. M. Davis, Management of Critically III Adults With 433 COVID-19, *JAMA* (2020), doi:10.1001/jama.2020.4914.

434 14. C. Fava, F. Cattazzo, Z.-D. Hu, G. Lippi, M. Montagnana, The role of red blood cell
435 distribution width (RDW) in cardiovascular risk assessment: useful or hype?, *Ann Transl*436 *Med* 7, 581 (2019).

- 437 15. J. Zhu, P. Ji, J. Pang, Z. Zhong, H. Li, C. He, J. Zhang, C. Zhao, Clinical
  438 characteristics of 3,062 COVID-19 patients: a meta-analysis, *J. Med. Virol.* (2020),
  439 doi:10.1002/jmv.25884.
- 440 16. J. Liu, H. Li, M. Luo, J. Liu, L. Wu, X. Lin, R. Li, Z. Wang, H. Zhong, W. Zheng, Y.
- Zhou, D. Jiang, X. Tan, Z. Zhou, H. Peng, G. Zhang, Lymphopenia acted as an adverse
- factor for severity in patients with COVID-19: a single-centered, retrospective study *In Review* (2020).
- 17. L. Tan, Q. Wang, D. Zhang, J. Ding, Q. Huang, Y.-Q. Tang, Q. Wang, H. Miao,
  Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study, *Signal Transduct Target Ther* **5**, 33 (2020).
- 18. S. Shi, M. Qin, B. Shen, Y. Cai, T. Liu, F. Yang, W. Gong, X. Liu, J. Liang, Q. Zhao,
  H. Huang, B. Yang, C. Huang, Association of Cardiac Injury With Mortality in
  Hospitalized Patients With COVID-19 in Wuhan, China, *JAMA Cardiol* (2020),
  doi:10.1001/jamacardio.2020.0950.
- 451 19. A. N. Kochi, A. P. Tagliari, G. B. Forleo, G. M. Fassini, C. Tondo, Cardiac and
  452 arrhythmic complications in patients with COVID-19, *J. Cardiovasc. Electrophysiol.*453 (2020), doi:10.1111/jce.14479.
- 454 20. Y. Cheng, R. Luo, K. Wang, M. Zhang, Z. Wang, L. Dong, J. Li, Y. Yao, S. Ge, G.
  455 Xu, Kidney disease is associated with in-hospital death of patients with COVID-19,
  456 *Kidney Int.* (2020), doi:10.1016/j.kint.2020.03.005.
- 457 21. Y. Zhang, M. Xiao, S. Zhang, P. Xia, W. Cao, W. Jiang, H. Chen, X. Ding, H. Zhao,
  458 H. Zhang, C. Wang, J. Zhao, X. Sun, R. Tian, W. Wu, D. Wu, J. Ma, Y. Chen, D. Zhang,
  459 J. Xie, X. Yan, X. Zhou, Z. Liu, J. Wang, B. Du, Y. Qin, P. Gao, X. Qin, Y. Xu, W. Zhang,
  460 T. Li, F. Zhang, Y. Zhao, Y. Li, S. Zhang, Coagulopathy and Antiphospholipid Antibodies
  461 in Patients with Covid-19, *N. Engl. J. Med.* (2020), doi:10.1056/NEJMc2007575.
- 462 22. F. A. Klok, M. J. H. A. Kruip, N. J. M. van der Meer, M. S. Arbous, D. A. M. P. J.
- Gommers, K. M. Kant, F. H. J. Kaptein, J. van Paassen, M. A. M. Stals, M. V. Huisman,
- 464 H. Endeman, Incidence of thrombotic complications in critically ill ICU patients with
- 465 COVID-19, *Thromb. Res.* (2020), doi:10.1016/j.thromres.2020.04.013.

466 23. Y. Liu, Y. Yang, C. Zhang, F. Huang, F. Wang, J. Yuan, Z. Wang, J. Li, J. Li, C.

- 467 Feng, Z. Zhang, L. Wang, L. Peng, L. Chen, Y. Qin, D. Zhao, S. Tan, L. Yin, J. Xu, C.
- 468 Zhou, C. Jiang, L. Liu, Clinical and biochemical indexes from 2019-nCoV infected
- patients linked to viral loads and lung injury, *Sci. China Life Sci.* **63**, 364–374 (2020).

470 24. L. Wynants, B. Van Calster, M. M. J. Bonten, G. S. Collins, T. P. A. Debray, M. De

Vos, M. C. Haller, G. Heinze, K. G. M. Moons, R. D. Riley, E. Schuit, L. J. M. Smits, K. I.

472 E. Snell, E. W. Steyerberg, C. Wallisch, M. van Smeden, Prediction models for

diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal, *BMJ* 369 (2020), doi:10.1136/bmj.m1328.

- 25. J. Gong, J. Ou, X. Qiu, Y. Jie, Y. Chen, L. Yuan, J. Cao, M. Tan, W. Xu, F. Zheng,
  Y. Shi, B. Hu, A Tool to Early Predict Severe Corona Virus Disease 2019 (COVID-19) :
- A Multicenter Study using the Risk Nomogram in Wuhan and Guangdong, China, *Clin. Infect. Dis.* (2020), doi:10.1093/cid/ciaa443.
- 479 26. R. Witzig, The medicalization of race: scientific legitimization of a flawed social
  480 construct, *Ann. Intern. Med.* **125**, 675–679 (1996).
- 27. L. M. Hunt, N. D. Truesdell, M. J. Kreiner, Genes, race, and culture in clinical care:
  racial profiling in the management of chronic illness, *Med. Anthropol. Q.* 27, 253–271
  (2013).
- 28. C. Strobl, A.-L. Boulesteix, A. Zeileis, T. Hothorn, Bias in random forest variable
  importance measures: illustrations, sources and a solution, *BMC Bioinformatics* 8, 25
  (2007).

487 29. K. F. Boreskie, P. E. Boreskie, D. Melady, Age is just a number - and so is frailty:
488 Strategies to inform resource allocation during the COVID-19 pandemic, *CJEM*, 1–3
489 (2020).

- 30. A. J. Singer, E. J. Morley, M. C. Henry, Staying Ahead of the Wave, *N. Engl. J. Med.*(2020), doi:10.1056/NEJMc2009409.
- 492 31. H. M. Alger, J. H. Williams Iv, J. G. Walchok, M. M. Bolles, G. C. Fonarow, C.
- Rutan, The Role of Data Registries in the Time of COVID-19, *Circ. Cardiovasc. Qual.*
- 494 *Outcomes* (2020), doi:10.1161/CIRCOUTCOMES.120.006766.



#### Fig 1. Study Design and Workflow. 497

A) Procedure for patient inclusion in our study. B) Strategy and design for experiments. Patient clinical data from Mount 498 Sinai Hospital (MSH) was used to train and validate our machine learning model. We then test these models on patients 499 500 from four other external hospitals within the Mount Sinai Health System: Mount Sinai Brooklyn (MSB), Mount Sinai Morningside (MSM), Mount Sinai Queens (MSQ), and Mount Sinai West (MSW). C) Machine learning experimental 501

502 design. We train on data from admission to predict mortality and critical illness outcomes.



503 504

## 505 Fig 2. Machine learning experimental results.

In all plots, the orange line reflects training at Mount Sinai Hospital (MSH) and testing 506 507 via cross-validation. The blue line reflects testing the model built on patient data from MSH on external patients from all other hospitals (OH) A) Area under the receiver 508 operator characteristic curve (AUC-ROC) for predicting critical illness at seven days 509 since admission. B) Area under the precision-recall curves (AUPRC) for predicting 510 critical illness at seven days since admission. C) AUC for predicting mortality at seven 511 512 days since admission. D) AUPRC for predicting critical illness at seven days since 513 admission.



#### 516

### 517 Fig 3. SHAP Summary and Dependency Plots.

SHAP summary plots for critical event (A) and mortality (D) at 7 days show the SHAP values for the most important 518 features for the respective XGBoost model. Features in the summary plots (y-axis) are organized by their mean absolute 519 SHAP values (x-axis), which represents the importance of that feature in driving the classifier's prediction, for patients. 520 Values of those features for each patient (i.e. a particular LDH value) are colored by their relative value. (B) and (C) 521 represent dependency plots, which similarly demonstrate how different values of those features can affect the SHAP 522 score and ultimately impact classifier decisions, for prothrombin time (PT) and D-Dimer, respectively, for critical event 523 prediction. (E) and (F) represent dependency plots for age and procalcitonin levels. Patients with missing values for a 524 feature in the dependency plot are clustered in the shaded area to the left. 525

# 526 **Table 1.** Characteristics of Hospitalized Covid-19 Patients at Baseline (n= 3055)

527

Characteristics of Admission	MSH	Other locations
Demographics		
Sex, n (%)		
Male	704 (57.5)	1070 (58.5)
Female	521 (42.5)	760 (41.5)
Race, n (%)		
Other	537 (43.8)	749 (40.9)
Caucasian	293 (23.9)	435 (23.8)
African American	273 (22.3)	503 (27.5)
Unknown	64 (5.2)	60 (3.3)
Asian	44 (3.6)	65 (3.5)
Pacific Islander	14 (1.1)	18 (0.9)
Ethnicity, n (%)		
Non-Hispanic Latino	676 (55.2)	1133 (61.9)
Hispanic/Latino	333 (27.2)	503 (27.5)
Unknown	216 (17.6)	194 (10.6)
Age, Median (IQR)	62.1 (49.4-71.8)	68.33 (56.9-78.8)
Age group, n (%)		
18-30	56 (4.6)	37 (2.0)
31-40	139 (11.6)	93 (5.1)
41-50	133 (10.9)	158 (8.6)
51-60	242 (19.8)	309 (16.9)
61-70	320 (26.1)	431 (23.5)
71-80	202 (16.5)	422 (23.1)
81-90	102 (8.3)	308 (16.8)
At least 90	31 (2.5)	72 (3.9)
Previous Medical History, n (%)		
Hypertension (%)	462 (37.7)	686 (37.5)
Atrial Fibrillation (%)	86 (7.0)	130 (7.1)
Coronary Artery Disease (%)	171 (13.9)	307 (16.8)
Heart failure (%)	110 (8.9)	181 (9.9)
Stroke (%)	98 (8)	118 (6.5)

		1						
Chronic Kidney Disease (%)	136 (11.1)	158 (8.6)						
Diabetes (%)	313 (25.5)	466 (25.5)						
Asthma (%)	115 (9.4)	132 (7.2)						
Chronic Obstructive Pulmonary Disease (%)	65 (5.3)	103 (5.6)						
Cancer (%)	112 (9.1)	94 (5.1)						
Vital Signs at Hospital Admission, Mediar	(IQR)							
Heart Rate (bpm)	89 (78 -100)	89 (78 - 100)						
Pulse Oximetry (%)	96 (94 - 98)	96 (94 - 98)						
Respiration Rate (breaths / minute)	20 (18 - 20)	18 (18 - 20)						
Temperature (F)	98.7 (98.1 - 99.9)	97.9 (98.6 - 99.5)						
Systolic Blood Pressure (mmHg)	124 (112 - 138)	127 (112 - 142)						
Diastolic Blood Pressure (mmHg)	69 (61 - 78)	72 (65 - 81)						
Weight (kg)	80.9 (68.9 - 95.3)	78.9 (68.04 - 91.7)						
Admission Laboratory Parameters, Median (IQR)								
Metabolic markers	r	r						
Sodium (mEq/L)	137 (135 - 140)	138 (135 -141)						
Potassium (mEq/L)	4 (3.6 - 4.5)	4.2 (3.9 - 4.7)						
Creatinine (mg/dL)	0.9 (0.7 - 1.4)	1.0 (0.8 -1.6)						
Lactate (mg/dL)	1.7 (1.3 - 2.2)	1.4 (1.1 - 2.0)						
Hematological markers								
White Blood Cells (10 <sup>3</sup> /µL)	6.8 (5.2 - 9.8)	7.7 (5.7 - 10.5)						
Lymphocyte Percentage	13.1 (7.8 - 20.7)	14.1 (8.9 - 21.4)						
Hemoglobin (mEq/L)	12.5 (11.1 - 13.7)	12.8 (11.4 - 14)						
Red Blood Cell Distribution Width (%)	14.4 (13.6 -15.6)	12.7 (12.1 - 13.9)						
Platelets (#)	212 (162 - 279.3)	194 (148 - 260)						
Liver Function								
Alanine Aminotransferase (units/L)	31 (19 - 54)	31 (20 - 53)						
Aspartate Aminotransferase (units/L)	41.5 (29 - 67)	47 (31 - 74)						
Albumin (g/dL)	3 (2.6 - 3.3)	3 (2.6 - 3.3)						
Total Bilirubin (mg/dL)	0.6 (0.4 - 0.8)	0.6 (0.4 - 0.8)						
Coagulation markers								
Prothrombin Time (s)	14.3 (13.5 - 15.7)	14.2 (13.5 - 15.5)						
Partial Thromboplastin Time (s)	32.5 (29.2 - 37.1)	33.3 (30 - 38.8)						
	32.5 (29.2 - 37.1)	33.3 (30 - 38.8)						

Gases								
PCO <sub>2</sub> (mmHg)	37 (41 - 47)	41 (35 - 47)						
рН	7.4 (7.4 - 7.4)	7.4 (7.3 - 7.4)						
Inflammatory markers								
C Reactive Protein (mg/L)	152.3 (83.1 - 205.6)	124.6 (62.3 - 214.5)						
Ferritin (ng/mL)	720 (343.5 - 1813.8)	818 (388 - 1966)						
D-Dimer (ng/mL)	1.3 (0.7 - 2.5)	1.5 (0.9 - 3.0)						
Creatinine Phosphokinase (units/L)	156 (80 - 505)	237.5 (187.8 - 440.5)						
Lactate Dehydrogenase (units/L)	417 (315 - 559)	450 (346.3 - 610.8)						
Procalcitonin (ng/mL)	0.2 (0.1 - 0.6)	0.2(0.1 - 0.7)						
Cardiac markers								
Troponin I (ng/mL)	0.1 (0.02 - 0.2)	0.2 (0.1- 0.9)						



# 531 Supplementary Fig 1.SHAP Interactions: Critical Event at 7 Days.

532 Heatmap demonstrating the composite SHAP interaction scores between features for patients from the best performing k-

533 th validation fold for critical event prediction at 7 days. The intensity along the diagonal represents independent

534 contributions of a feature towards model prediction (i.e. mean absolute SHAP values in Figure 3). Covariant interactions

535 between features is significantly less relative to the intensity of the independent contributions of each feature towards

536 model prediction.



539 Supplementary Fig 2. SHAP Interactions: Critical Event at 7 Days (Univariate Effect Removal).

- 540 Heatmap demonstrating the composite SHAP interaction scores between features for patients from the best performing k-
- 541 th validation fold for critical event prediction at 7 days. Univariate feature contributions along the diagonal have been set to
- 542 0 to better examine the relative strength of covariance between features.



#### 544

### 545 Supplementary Fig 3. SHAP Interactions: Mortality at 7 Days.

546 Heatmap demonstrating the composite SHAP interaction scores between features for patients from the best performing k-

547 th validation fold for mortality prediction at 7 days. The intensity along the diagonal represents independent contributions

of a feature towards model prediction (i.e. mean absolute SHAP values in Figure 3). Covariant interactions between

549 features is significantly less relative to the intensity of the independent contributions of each feature towards model

550 prediction.



552

553 Supplementary Fig 4. SHAP Interactions: Mortality at 7 Days (Univariate Effect Removal).

554 Description: Heatmap demonstrating the composite SHAP interaction scores between features for patients from the best

555 performing k-th validation fold for mortality prediction at 7 days. Univariate feature contributions along the diagonal have

556 been set to 0 to better examine the relative strength of covariance between features.



558 Supplementary Fig 5. Importance of Age Over Time Frames

560 time frames (7, 10, 15, and 20 days).

<sup>559</sup> Mean absolute SHAP value for age (blue) to represent importance in prediction of critical event occurrence over different

# 561 Supplementary Table 1. Baseline Patient Characteristics by Hospital.

562 Characteristics, such demographics, clinical history, vital signs, and laboratory tests, for

all patients included in the study and delineated by the hospital site at which the patientwas admitted.

Characteristics or Admission	MSQ	MSB	MSH	MSW	MSM
Demographics					
Sex, n (%)					
Male	291 (63.4)	207 (58.9)	317 (56.6)	255 (55.4)	704 (57.47)
Female	168 (36.6)	144 (41.0)	243 (43.4)	205 (44.6)	521 (42.53)
Race, n (%)					
Other	33 (7.2)	9 (1.9)	44 (3.6)	16 (4.6)	7 (1.3)
African American	50 (10.9)	191 (41.5)	273 (22.3)	68 (19.4)	194 (34.6)
Caucasian	264 (57.5)	91 (19.8)	537 (43.8)	131 (37.3)	263 (46.9)
Asian	9 (1.9)	0 (0)	14 (1.1)	4 (1.1)	5 (0.9)
Pacific Islander	16 (3.5)	19 (4.1)	64 (5.2)	5 (1.4)	20 (3.6)
Unknown	87 (18.9)	150 (32.6)	293 (23.9)	127 (36.2)	71 (12.7)
Ethnicity, n (%)					
Hispanic/Latino	230 (50.1)	322 (70)	676 (55.2)	251 (71.5)	330 (58.9)
Non-Hispanic Latino	188 (40.9)	17 (3.7)	333 (27.2)	92 (26.2)	206 (36.8)
Unknown	41 (8.9)	121 (26.3)	216 (17.6)	8 (2.3)	24 (4.3)
Age - Median(IQR)	66 (56-77)	65.3 (51.7-76.4)	68.8 (56.0-80.1)	72 (63-82)	62.1 (49.4-71.8)
Age group, n (%)		r			
18-30	10 (2.2)	16 (4.6)	7 (1.3)	4 (0.9)	56 (4.6)
31-40	16 (3.5)	38 (10.8)	32 (5.7)	7 (1.5)	139 (11.4)
41-50	49 (10.7)	32 (9.1)	60 (10.7)	17 (3.7)	133 (10.9)
51-60	92 (20.0)	62 (17.7)	90 (16.1)	65 (14.1)	242 (19.8)
61-70	110 (23.9)	71 (20.2)	123 (21.9)	127 (27.6)	320 (26.1)
71-80	108 (23.5)	73 (20.8)	120 (21.4)	121 (26.3)	202 (16.5)
81-90	64 (13.9)	51 (14.5)	101 (18.0)	92 (20)	102 (8.3)
At least 90	10 (2.2)	8 (2.3)	27 (4.8)	27 (5.9)	31 (2.5)
Previous Medical History, n (%	)				
Hypertension (%)	228 (49.7)	120 (34.2)	210 (37.5)	128 (27.8)	462 (37.7)

	1			1	1
Atrial Fibrillation (%)	45 (9.8)	18 (5.1)	40 (7.1)	27 (5.9)	86 (7.0)
Coronary Artery Disease (%)	95 (20.7)	46 (13.1)	85 (15.2)	81 (17.6)	171 (13.9)
Heart failure (%)	51 (11.1)	27 (7.7)	61 (10.9)	42 (9.1)	110 (8.9)
Stroke (%)	43 (9.4)	22 (6.3)	39 (6.9)	14 (3.0)	98 (8)
Chronic Kidney Disease (%)	54 (11.8)	20 (5.7)	58 (10.4)	26 (5.6)	136 (11.1)
Diabetes (%)	154 (33.6)	68 (19.4)	143 (25.5)	101 (21.9)	313 (25.6)
Asthma (%)	42 (9.2)	32 (9.1)	45 (8.0)	13 (2.8)	115 (9.4)
Chronic Obstructive Pulmonary Disease (%)	35 (7.6)	16 (4.6)	31 (5.5)	21 (4.6)	65 (5.1)
Cancer (%)	20 (4.4)	30 (8.5)	33 (5.9)	11 (2.4)	112 (9.1)
Vital Signs at Hospital Admiss	ion, Median (IQR)				
Heart Rate (bpm)	89 (78 – 101)	89 (78-100.2)	89 (78-100)	85 (76-96)	89 (79-101.3)
Oxygen Saturation (%)	95 (93-97)	96 (94-98)	96 (94-98)	96 (94.5-98)	96 (94-98)
Respiration Rate (breaths / minute)	18 (18-20)	18 (18-19.3)	20 (18-22)	18 (17- 20)	20 (18-22)
Temperature (F)	98.8 (98.2-99.7)	98 (97.3-98.7)	98.7 (98.1-99.9)	98.7 (98-99.6)	99 (98.2-100)
Systolic Blood Pressure (mmHg)	70 (63-78)	70 (62.75-80)	69 (61-78)	74 (65.5-84)	74 (66.8-82)
Diastolic Blood Pressure (mmHg)	123 (110-138)	130 (112-145)	124 (112-138)	126 (111-137)	128.5 (114-144)
Weight (kg)	76.3 (65.2-90.7)	79.4 (68.1-92.9)	80.9 (69.0-95.3)	78.8 (67.6-90.7)	79.6 (69.1-92.2)
Admission Laboratory Parame	ters, Median (IQR)				
Metabolic Markers					
Sodium (mEq/L)	138 (136-141)	139 (137-142)	137 (135-140)	137 (134-139)	138 (135-141)
Potassium (mEq/L)	4.3 (3.9-4.7)	4.3 (3.8-4.7)	4 (3.6-4.5)	4.2 (3.9-4.7)	4.2 (3.8-4.7)
Creatinine (mg/dL)	1 (0.8-2.1)	1.2 (0.9-2.1)	0.9 (0.7-1.4)	0.9 (0.7-1.3)	1.0 (0.8-1.7)
Lactate (mg/dL)	-	1.94 (1.1-2.9)	1.7 (1.3-2.2)	1.5 (1.1-2)	1.3 (1-1.8)
Hematological Markers					
White Blood Cells (103/µL)	7.9 (5.9-10.5)	7.5 (5.4-10.5)	6.8 (5.2-9.8)	7.7 (5.6-10.9)	7.5 (5.7-10.5)
Lymphocyte Percentage	12 (7.1-18.3)	14.7 (8.9-22.7)	13.1 (7.8-20.1)	16.1 (9.6-23.1)	13.05 (9-20.5)
Hemoglobin (mEq/L)	12.6 (11.1-13.8)	12.5 (11.2-13.8)	12.5 (11.1-13.7)	13 (11.6-14.2)	13 (11.6-14)

Red Blood Cell Distribution	12.8	13.1	14.4	12.5	12.6
Width (%)	(12.1-14.2)	(12.5-14.1)	(13.6-15.6)	(12-13.5)	(12.1-13.7)
Platelets (#)	188	205.5	212	197	187
	(146-259)	(153-266.2)	(162-279.3)	(152-264)	(144-252)
Liver Function					
Alanine Aminotransferase	34	28	31	30	32
(units/L)	(21-55)	(19-49)	(19-54)	(19-54)	(19-54.8)
Aspartate Aminotransferase (units/L)	50	42	41.5	48.5	45
	(34-76.8)	(28-74)	(29-67)	(32-77)	(31-71)
Albumin (g/dL)	2.7	3.4	3	3	2.9
	(2.3-3.2)	(3.1-3.7)	(2.6-3.3)	(2.6-3.3)	(2.5-3.1)
Total Bilirubin (mg/dL)	0.6	0.6	0.6	0.5	0.6
	(0.4-0.7)	(0.4-0.7)	(0.4-0.8)	(0.4-0.8)	(0.4-0.8)
Coagulation Markers					
Prothrombin Time (s)	14	14.6	14.3	13.9	14.2
	(13.4-17.2)	(13.5-16.1)	(13.5-15.7)	(13.4-14.9)	(13.6-15.3)
Partial Thromboplastin	35.7	35.2	32.5	32.1	32.9
Time (s)	(32.2-61.2)	(32.3-38.6)	(29.2-37.2)	(29.8-37.5)	(29.4-38.7)
Gases					
PCO2 (mmHg)	-	40 (34.3-46)	41 (37-47)	41.5 (36.3-48)	41 (35-47)
рН					7.4 (7.3-7.4)
	-	7.4 (7.3-7.4)	7.4 (7.4-7.4)	7.4 (7.3-7.4)	
Inflammatory Markers					
C Reactive Protein (mg/L)	207.2	147.7	152.3	104.9	125.4
	(159.4-233.4)	(90.7-243.3)	(83.1-205.6)	(50.6-190.4)	(62.7-201.6)
Ferritin (ng/mL)	968	999.5	720	713.5	763
	(473.6-2378.3)	(522.2-2228.5)	(343.5-1813.8)	(305.8-1466)	(360- 1784)
D-Dimer (ng/mL)	1.5	2.3	1.3	1.4	1.5
	(1.0-2.9)	(1.1-4.1)	(0.7-2.5)	(0.7-2.6)	(0.9-2.9)
Creatinine Phosphokinase (units/L)	237.5 (187.8-440.5)	-	156 (80-505)	-	-
Procalcitonin (ng/mL)	0.3	0.4	0.2	0.2	0.2
	(0.1-0.8)	(0.2-1.4)	(0.1-0.6)	(0.1-0.5)	(0.1-0.7)
Lactate Dehydrogenase	468	489	417	448	427
(units/L)	(359.5-628)	(390-637.5)	(315-559)	(345-651.5)	(324-559)
Cardiac Markers					
Troponin I (ng/mL)	0.2 (0.1-0.9)	-	0.1 (0.0-0.2)	-	-
Outcomes					
Critical	0	0	0	0	0
	(0-1)	(0-1)	(0-1)	(0-1)	(0-1)
Mortality	0	0	0	0	0
	(0-0)	(0-0)	(0-0)	(0-0)	(0-0)

# 566 **Supplementary Table 2. Baseline Patient Feature Analysis.**

567 Missingness, means, standard deviations, interquartile ranges, and histograms for all

- 568 features in the dataset.
- 569

Variable	Missing (N)	Present (%)	Mean	Standard Deviation	IQR - 0%	IQR - 25%	IQR - 50%	IQR - 75%	IQR - 100%	Histogram
Demographics					l					
Age	0	100%	64.5	16.5	18.3	54.4	65.7	76.5	102	
Sex	0	100%	0.581	0.494	0	0	1	1	1	<b>.</b>
ED Admission	0	100%	0.973	0.164	0	1	1	1	1	
Other Admission Type	0	100%	0.113	0.316	0	0	0	0	1	<b>I</b>
Never Smokers	0	100%	0.521	0.5	0	0	1	1	1	<b>BB</b>
Smoking Status: Never Asked	0	100%	0.0426	0.202	0	0	0	0	1	<b>I</b>
Passive Smokers	0	100%	0.000982	0.0313	0	0	0	0	1	<b>I</b>
Former Smokers	0	100%	0.205	0.403	0	0	0	0	1	<b>I</b>
Active Smokers	0	100%	0.0383	0.192	0	0	0	0	1	<b>I</b>
Asian	0	100%	0.0357	0.186	0	0	0	0	1	<b></b>
African American	0	100%	0.254	0.435	0	0	0	1	1	<b>B</b>
Other Race	0	100%	0.421	0.494	0	0	0	1	1	<b>B</b>
Pacific Islander	0	100%	0.0105	0.102	0	0	0	0	1	<b></b>
Unknown Race	0	100%	0.0406	0.197	0	0	0	0	1	<b></b>
White	0	100%	0.238	0.426	0	0	0	0	1	<b>.</b>
Hispanic	0	100%	0.274	0.446	0	0	0	1	1	<b>.</b>
Non-Hispanic	0	100%	0.592	0.492	0	0	1	1	1	
Unknown Ethnicity	0	100%	0.134	0.341	0	0	0	0	1	<b></b>
Past Medical History										

Atrial Fibrillation	0	100%	0.0707	0.256	0	0	0	0	1	<b></b>
Asthma	0	100%	0.0809	0.273	0	0	0	0	1	<b></b>
CAD	0	100%	0.156	0.363	0	0	0	0	1	B
Cancer	0	100%	0.0674	0.251	0	0	0	0	1	<b></b>
СКD	0	100%	0.0962	0.295	0	0	0	0	1	<b></b>
COPD	0	100%	0.055	0.228	0	0	0	0	1	<b></b>
Diabetes	0	100%	0.255	0.436	0	0	0	1	1	B
Heart Failure	0	100%	0.0953	0.294	0	0	0	0	1	<b></b>
Hypertension	0	100%	0.376	0.484	0	0	0	1	1	BB
Stroke	0	100%	0.0707	0.256	0	0	0	0	1	<b></b>
Vitals										
Pulse	0	100%	89.5	16.7	46	78	89	100	150	<b></b>
Pulse Oximetry	11	100%	95.2	3.24	76	94	96	98	99	<b>_</b>
Respiration Rate	4	100%	20.2	4.2	7	18	19	20	46	
Temperature	6	100%	98.9	1.4	95.2	98	98.7	99.7	103	
Diastolic BP	5	100%	71.7	12.2	39	63	71	80	107	
Systolic BP	6	100%	127	21.3	72	112	126	140	189	
Weight	192	94%	82.5	20.6	40	68	79.6	93	174	<b>_B_</b>
Labs										
ALT	111	96%	47.5	56.1	8	19	31	54	597	<b></b>
AST	124	96%	64.9	73.4	13	30	44	72	905	<b></b>
CRP	1901	38%	144	94.8	1.91	63.7	127	215	457	
D-Dimer	763	75%	2.53	3.15	0.28	0.79	1.43	2.75	18.8	<b></b>
Ferritin	546	82%	1529	2161	36	369	776	1901	17466	<b></b>
LDH	588	81%	498	261	171	328	436	585	2165	<b>I.</b>
Procalcitonin	661	78%	1.71	7.64	0.03	0.09	0.21	0.68	154	<b>I</b>

WBC	9	100%	8.39	4.31	1.9	5.4	7.4	10.3	40	<b>Ba</b>
Albumin	885	71%	2.97	0.518	1.2	2.6	3	3.3	4.1	
СРК	2768	9%	435	757	17	82.5	173	500	8103	<b>I</b>
Creatinine	667	78%	1.73	2.22	0.37	0.74	0.97	1.55	16.1	<b></b>
Hemoglobin	669	78%	12.5	2.01	6.2	11.3	12.7	13.9	17.1	
Lactate	1703	44%	1.86	1.09	0.7	1.2	1.6	2.2	9.9	<b>I</b>
Lymphocyte (%)	871	72%	15.7	9.58	1	8.5	13.6	20.9	54.1	
PCO2	2087	32%	42.4	9.54	23	36	41	47	87	<b></b>
рН	2085	32%	7.38	0.0833	7.01	7.35	7.39	7.43	7.53	<b>_</b>
Platelets	668	78%	221	97.8	27	155	202	268	734	<b>sl.</b>
Potassium	641	79%	4.21	0.684	2.9	3.7	4.1	4.6	7	<b>=L</b>
PT	2284	25%	15.4	4.25	12.2	13.5	14.3	15.6	48.1	<b>I</b>
PTT	2293	25%	36.2	13.6	22	29.6	32.9	38	153	<b>I</b>
RDW	688	78%	14	2.12	11.1	12.6	13.6	14.8	25.9	
Sodium	639	79%	138	5.48	123	135	138	141	163	_ <b>B</b>
Bilirubin (Total)	984	68%	0.691	0.445	0.3	0.4	0.6	0.8	4.4	<b>I</b>
Troponin-I	2605	15%	0.589	1.78	0.01	0.02	0.06	0.24	15.9	<b>I</b>
Outcomes										
Critical Event	0	100%	0.166	0.372	0	0	0	0	1	<b></b>
Mortality	0	100%	0.0606	0.239	0	0	0	0	1	

# 571 Supplementary Table 3. Final XGBoost Model Hyperparameters.

572 Final hyperparameters for the XGBoost classifier at day 7 for critical event and mortality 573 prediction after tuning using a grid-search to optimize for AUC-ROC.

574

Hyperparameter	Critical	Critical outcome				Mortality				
	3 Days	5 Days	7 Days	10 Days	3 Days	5 Days	7 Days	10 Days		
reg_alpha	1.0	0.10	0.01	0.1	1.0	1.0	0.1	0.1		
min_child_weight	5.0	3.0	3.0	7.0	5.0	1.0	1.0	5.0		
max_depth	9.0	6.0	6.0	6.0	6.0	9.0	6.0	6.0		
learning_rate	0.05	0.05	0.05	0.05	0.05	0.05	0.05	0.1		
gamma	0.4	0.3	0.2	0.1	0.3	0.2	0.3	0.4		
colsample_bytree	0.3	0.3	0.4	0.3	0.3	0.3	0.3	0.5		

### 576 Supplementary Table 4. Model Performance Across Each Hospital.

577 Performance of the XGBoost classifier by hospital site, as measured by accuracy

578 (ACC), area under the receiver operating curve (AUCROC), area under the precision

recall curve (AUCPRC), F1-score (F1), sensitivity (SENS), and specificity (SPEC). "OH"

refers to all hospitals in the external validation set (i.e. MSW, MSM, MSB, MSQ).

581 Outcomes are structured by "<outcome>\_<day>", where outcome is either a critical

event (CRITICAL) or mortality (MORTALITY) and the time frame it was predicted over.

583 "OUTCOME PROP" refers to the portion of the dataset with the respective outcome.

FACILITY	OUTCOME	PATIENTS	PROP OUTCOME	ACC	AUCROC	AUCPRC	F1	SENS	SPEC
MSH	CRITICAL_3	1225	0.17	0.90	0.89	0.71	0.59	0.84	0.90
	CRITICAL_5	1156	0.22	0.84	0.84	0.67	0.53	0.75	0.85
	CRITICAL_7	1052	0.25	0.81	0.83	0.66	0.53	0.71	0.83
	CRITICAL_10	931	0.28	0.80	0.83	0.67	0.57	0.70	0.82
	MORTALITY_3	1225	0.03	0.97	0.87	0.26	0.03	1.00	0.97
	MORTALITY_5	1156	0.05	0.95	0.84	0.37	0.13	0.56	0.95
	MORTALITY_7	1052	0.07	0.93	0.87	0.49	0.21	0.71	0.94
	MORTALITY_10	931	0.12	0.90	0.84	0.50	0.36	0.65	0.91
MSQ	CRITICAL_3	459	0.20	0.81	0.79	0.52	0.21	0.60	0.82
	CRITICAL_5	440	0.29	0.73	0.79	0.59	0.21	0.67	0.73
	CRITICAL_7	414	0.36	0.69	0.77	0.65	0.31	0.71	0.68
	CRITICAL_10	390	0.41	0.69	0.80	0.73	0.46	0.80	0.67
	MORTALITY_3	459	0.14	0.86	0.77	0.42	0.00	-	0.86
	MORTALITY_5	440	0.23	0.80	0.76	0.56	0.21	0.92	0.79
	MORTALITY_7	414	0.30	0.74	0.77	0.61	0.25	0.86	0.73
	MORTALITY_10	390	0.37	0.68	0.78	0.67	0.29	0.74	0.67
MSB	CRITICAL_3	460	0.17	0.85	0.77	0.45	0.20	0.75	0.85
	CRITICAL_5	426	0.28	0.75	0.80	0.63	0.19	0.93	0.74
	CRITICAL_7	397	0.35	0.68	0.76	0.61	0.17	0.81	0.67
	CRITICAL_10	370	0.41	0.65	0.80	0.71	0.32	0.79	0.63
	MORTALITY_3	460	0.10	0.90	0.79	0.39	0.04	1.00	0.90
	MORTALITY_5	426	0.21	0.80	0.83	0.58	0.11	1.00	0.80
	MORTALITY_7	397	0.28	0.75	0.82	0.66	0.22	1.00	0.74
	MORTALITY_10	370	0.36	0.67	0.79	0.67	0.19	0.88	0.66
MSW	CRITICAL_3	351	0.12	0.89	0.81	0.46	0.31	0.53	0.90
	CRITICAL_5	331	0.15	0.86	0.78	0.45	0.43	0.57	0.89
	CRITICAL_7	307	0.16	0.87	0.81	0.52	0.44	0.64	0.89
	CRITICAL_10	280	0.20	0.83	0.80	0.58	0.49	0.59	0.87
	MORTALITY_3	351	0.02	0.98	0.89	0.09	0.00	-	0.98
	MORTALITY_5	331	0.03	0.97	0.86	0.23	0.00	-	0.97
	MORTALITY_7	307	0.05	0.95	0.88	0.38	0.00	0.00	0.95

	MORTALITY_10	280	0.07	0.95	0.80	0.41	0.40	1.00	0.95
MSM	CRITICAL_3	560	0.16	0.82	0.73	0.34	0.20	0.36	0.85
	CRITICAL_5	525	0.22	0.78	0.73	0.41	0.30	0.50	0.81
	CRITICAL_7	481	0.26	0.76	0.75	0.50	0.34	0.63	0.78
	CRITICAL_10	420	0.32	0.75	0.78	0.64	0.50	0.68	0.76
	MORTALITY_3	560	0.06	0.94	0.89	0.43	0.00	-	0.94
	MORTALITY_5	525	0.10	0.90	0.87	0.48	0.04	1.00	0.90
	MORTALITY_7	481	0.14	0.87	0.84	0.49	0.14	1.00	0.87
	MORTALITY_10	420	0.20	0.84	0.84	0.61	0.34	0.82	0.84
ОН	CRITICAL_3	1830	0.17	0.84	0.77	0.43	0.23	0.57	0.85
	CRITICAL_5	1722	0.24	0.78	0.76	0.51	0.26	0.65	0.79
	CRITICAL_7	1599	0.29	0.73	0.74	0.52	0.30	0.60	0.75
	CRITICAL_10	1460	0.34	0.73	0.79	0.66	0.44	0.77	0.73
	MORTALITY_3	1830	0.08	0.92	0.83	0.38	0.03	1.00	0.92
	MORTALITY_5	1722	0.15	0.86	0.82	0.52	0.08	1.00	0.86
	MORTALITY_7	1599	0.20	0.82	0.84	0.58	0.18	0.86	0.82
	MORTALITY_10	1460	0.26	0.79	0.83	0.64	0.40	0.74	0.79
					·	· ·		·	

#### 587

# 588 Supplementary Table 5. Model Performance At Extended Time Frames.

Performance of the XGBoost classifier on validation set from MSH and external 589 590 validation set (MSB, MSW, MSQ, MSM), as measured by accuracy (ACC), area under the receiver operating curve (AUCROC), area under the precision recall curve 591 (AUCPRC), F1-score (F1), sensitivity (SENS), and specificity (SPEC). "OH" refers to all 592 hospitals in the external validation set (i.e. MSW, MSM, MSB, MSQ). Outcomes are 593 structured by "<outcome>\_<day>", where outcome is either a critical event (CRITICAL) 594 or mortality (MORTALITY) and the time frame it was predicted over. "OUTCOME 595 PROP" refers to the portion of the dataset with the respective outcome. 596 597

FACILITY	OUTCOME	PATIENTS	PROP OUTCOME	ACC	AUCROC	AUCPRC	F1	SENS	SPEC
MSH	CRITICAL_15	792	0.27	0.81	0.84	0.68	0.60	0.71	0.84
	CRITICAL_20	719	0.25	0.82	0.85	0.68	0.58	0.70	0.85
	MORTALITY_15	792	0.16	0.87	0.86	0.58	0.58	0.64	0.89
	MORTALITY_20	719	0.18	0.86	0.87	0.64	0.54	0.67	0.87
ОН	CRITICAL_15	1320	0.37	0.72	0.75	0.66	0.53	0.68	0.73
	CRITICAL_20	1254	0.36	0.75	0.81	0.71	0.57	0.75	0.75
	MORTALITY_15	1320	0.32	0.74	0.81	0.65	0.40	0.75	0.74
	MORTALITY_20	1254	0.34	0.75	0.84	0.72	0.51	0.77	0.75

598

599

# 601 Supplementary Table 6. Logistic Regression and Generalized Additive Model

#### 602 **Performance.**

603 Performance of the four models using only Age and all the features, as measured by

accuracy (ACC), area under the receiver operating curve (AUCROC), area under the

605 precision recall curve (AUCPRC), F1-score (F1), sensitivity (SENS), and specificity

606 (SPEC). Models are structured by "<model>\_<feature space>", where model is either a

logistic regression (LOG) or generalized additive model (GAM) and the features used in
 the model.

MODEL	OUTCOME	PATIENTS	PROP OUTCOME	ACC	AUCROC	AUCPRC	F1	SENS	SPEC
LOG_AGE	CRITICAL_3	3055	0.17	0.83	0.57	0.22	0	1	0
	MORTALITY_3	3055	0.06	0.92	0.70	0.18	0	1	0
GAM_AGE	CRITICAL_3	3055	0.17	0.83	0.52	0.19	0.01	1	0.003
	MORTALITY_3	3055	0.06	0.98	0.62	0.14	0	1	0
LOG_ALL	CRITICAL_3	1278	0.18	0.81	0.74	0.33	0.31	0.90	0.29
	MORTALITY_3	1278	0.02	0.96	0.67	0.06	0.07	0.98	0.07
GAM_ALL	CRITICAL_3	1278	0.18	0.82	0.74	0.37	0.35	0.92	0.31
	MORTALITY_3	1278	0.02	0.98	0.62	0.14	0	1	0